Table 1.
Safety and efficacy in patients receiving a 2.25 mm taxus Express Atom stent in the taxus V de novo study
| Parameter | TAXUS V | ||
|---|---|---|---|
|
|
|||
| Patients receiving a 2.25 mm stent | |||
|
|
|||
| TAXUS Express atom (n = 108) | BMS Express (n = 95) | P-value | |
| Angiographic follow-up21 | 9 Months | ||
| In-stent late loss, mm | 0.49 ± 0.61 | 0.90 ± 0.63 | <0.001 |
| In-stent binary restenosis | 24.7% | 44.7% | 0.007 |
| Clinical follow-up21 | 9 Months | ||
| TLR | 10.4% | 21.5% | 0.03 |
| TVR | 16.0% | 24.7% | 0.16 |
| MACE* | 18.9% | 26.9% | 0.23 |
| Cardiac death | 1.9% | 1.1% | >0.99 |
| ST# | 1.0% | 1.1% | >0.99 |
| Follow-up42 | 12 Months | ||
| TLR | 14.6% | 24.9% | 0.047 |
| TVR | 22.6% | 30.4% | 0.26 |
| MACE* | 26.4% | 32.6% | 0.35 |
| Cardiac death | 2.8% | 1.2% | 0.63 |
| ST# | 1.0% | 1.1% | >0.99 |
| Follow-up43 | 36 Months | ||
| TLR | 19.6 | 27.1 | 0.13 |
Notes:
*
Includes cardiac death, myocardial infarction, and target vessel revascularization.
#
Per protocol definition.
Abbreviations: BMS, bare metal stent; TLR, target lesion revascularization; TVR, target vessel revascularization; MACE, major adverse cardiac event; ST, stent thrombosis.